Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C6IQ
|
||||
| Former ID |
DIB007068
|
||||
| Drug Name |
Stamulumab
|
||||
| Synonyms |
MYO-028; MYO-029; RK-35; GDF-8 program, Wyeth BioPharma/Genetics Institute; Anti-myostatin antibody, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Cambridge Antibody Technology/Wyeth; GDF-8 program, MetaMorphix/Wyeth BioPharma/Cambridge Antibody Technology
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Duchenne muscular dystrophy [ICD10:G71.0] | Phase 1/2 | [521630] | ||
| Company |
Wyeth
|
||||
| CAS Number |
CAS 705287-60-1
|
||||
| Target and Pathway | |||||
| Target(s) | Growth/differentiation factor 8 | Target Info | [544346] | ||
| PANTHER Pathway | TGF-beta signaling pathway | ||||
| WikiPathways | Hypertrophy Model | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.